Tyra Biosciences, Inc. Financials
This page shows Tyra Biosciences, Inc. (TYRA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Tyra Biosciences, Inc. passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Tyra Biosciences, Inc. generates $0.81 in operating cash flow (-$69.8M OCF vs -$86.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Tyra Biosciences, Inc.'s EBITDA was -$103.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 30.2% from the prior year.
Tyra Biosciences, Inc. generated -$70.4M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 38.4% from the prior year.
Tyra Biosciences, Inc. reported -$86.5M in net income in fiscal year 2024. This represents a decrease of 25.1% from the prior year.
Tyra Biosciences, Inc. earned $-1.51 per diluted share (EPS) in fiscal year 2024. This represents an increase of 6.8% from the prior year.
Tyra Biosciences, Inc. held $92.0M in cash against $0 in long-term debt as of fiscal year 2024.
Tyra Biosciences, Inc. had 51M shares outstanding in fiscal year 2024. This represents an increase of 18.0% from the prior year.
Tyra Biosciences, Inc. invested $80.1M in research and development in fiscal year 2024. This represents an increase of 28.1% from the prior year.
Tyra Biosciences, Inc. invested $664K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 13.8% from the prior year.
TYRA Income Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $25.5M+12.2% | $22.7M | N/A | $19.3M | N/A | $10.9M | N/A | $5.5M |
| SG&A Expenses | $7.5M+26.5% | $5.9M | N/A | $0 | N/A | $173K | N/A | $1.2M |
| Operating Income | -$32.9M-15.2% | -$28.6M | N/A | -$24.0M | N/A | -$13.6M | N/A | -$6.6M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$29.9M-24.4% | -$24.0M | N/A | -$21.2M | N/A | -$12.5M | N/A | -$6.6M |
| EPS (Diluted) | $-0.50-22.0% | $-0.41 | N/A | $-0.49 | N/A | $-0.30 | N/A | $-0.72 |
TYRA Balance Sheet
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $301.9M-17.0% | $363.6M+61.0% | $225.9M-5.2% | $238.4M-10.5% | $266.2M-3.6% | $276.0M-10.0% | $306.7M-2.9% | $316.0M |
| Current Assets | $281.2M-19.1% | $347.5M+64.2% | $211.7M-5.8% | $224.6M-12.7% | $257.3M-3.8% | $267.5M-12.0% | $304.1M-3.0% | $313.5M |
| Cash & Equivalents | $62.0M-32.6% | $92.0M+58.5% | $58.0M-73.1% | $215.7M-14.2% | $251.2M-4.6% | $263.2M-12.9% | $302.2M-3.4% | $312.8M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $21.3M+4.6% | $20.4M-5.5% | $21.6M+33.4% | $16.2M+93.8% | $8.4M+1.5% | $8.2M+65.8% | $5.0M-20.4% | $6.2M |
| Current Liabilities | $15.9M+8.8% | $14.6M-4.8% | $15.3M+51.1% | $10.1M+78.0% | $5.7M+3.9% | $5.5M+51.8% | $3.6M-24.2% | $4.8M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $280.5M-18.3% | $343.2M+68.0% | $204.3M-8.1% | $222.2M-13.8% | $257.8M-3.7% | $267.8M-11.3% | $301.7M-2.6% | $309.7M |
| Retained Earnings | -$337.4M-34.3% | -$251.3M-52.5% | -$164.8M-16.1% | -$142.0M-48.4% | -$95.7M-15.6% | -$82.8M-105.1% | -$40.4M-32.6% | -$30.4M |
TYRA Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$22.4M-14.2% | -$19.6M-44.8% | -$13.5M+21.1% | -$17.1M-43.1% | -$12.0M+1.9% | -$12.2M-35.3% | -$9.0M-61.9% | -$5.6M |
| Capital Expenditures | $39K+550.0% | $6K-99.0% | $603K+626.5% | $83K+295.2% | $21K-56.3% | $48K-54.3% | $105K-59.0% | $256K |
| Free Cash Flow | -$22.4M-14.4% | -$19.6M-38.6% | -$14.1M+18.0% | -$17.2M-43.6% | -$12.0M+2.1% | -$12.3M-34.2% | -$9.1M-56.5% | -$5.8M |
| Investing Cash Flow | -$14.8M-312.8% | $7.0M+104.8% | -$144.4M-173921.7% | -$83K-295.2% | -$21K+56.3% | -$48K+54.3% | -$105K+56.3% | -$240K |
| Financing Cash Flow | $647K-8.4% | $706K+117.9% | $324K-30.6% | $467K+15466.7% | $3K-99.2% | $364K+124.1% | -$1.5M-100.8% | $183.4M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
TYRA Financial Ratios
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -9.9%-3.6pp | -6.3% | N/A | -8.9% | N/A | -4.5% | N/A | -2.1% |
| Current Ratio | 17.71-6.1 | 23.81+10.0 | 13.80-8.3 | 22.14-23.0 | 45.13-3.6 | 48.73-35.4 | 84.09+18.3 | 65.75 |
| Debt-to-Equity | 0.08+0.0 | 0.06-0.0 | 0.11+0.0 | 0.07+0.0 | 0.030.0 | 0.03+0.0 | 0.020.0 | 0.02 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Tyra Biosciences, Inc. profitable?
No, Tyra Biosciences, Inc. (TYRA) reported a net income of -$86.5M in fiscal year 2024.
What is Tyra Biosciences, Inc.'s earnings per share (EPS)?
Tyra Biosciences, Inc. (TYRA) reported diluted earnings per share of $-1.51 for fiscal year 2024. This represents a 6.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Tyra Biosciences, Inc.'s EBITDA?
Tyra Biosciences, Inc. (TYRA) had EBITDA of -$103.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Tyra Biosciences, Inc.'s free cash flow?
Tyra Biosciences, Inc. (TYRA) generated -$70.4M in free cash flow during fiscal year 2024. This represents a -38.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Tyra Biosciences, Inc.'s operating cash flow?
Tyra Biosciences, Inc. (TYRA) generated -$69.8M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Tyra Biosciences, Inc.'s total assets?
Tyra Biosciences, Inc. (TYRA) had $363.6M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Tyra Biosciences, Inc.'s capital expenditures?
Tyra Biosciences, Inc. (TYRA) invested $664K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Tyra Biosciences, Inc. spend on research and development?
Tyra Biosciences, Inc. (TYRA) invested $80.1M in research and development during fiscal year 2024.
How many shares does Tyra Biosciences, Inc. have outstanding?
Tyra Biosciences, Inc. (TYRA) had 51M shares outstanding as of fiscal year 2024.
What is Tyra Biosciences, Inc.'s current ratio?
Tyra Biosciences, Inc. (TYRA) had a current ratio of 23.81 as of fiscal year 2024, which is generally considered healthy.
What is Tyra Biosciences, Inc.'s debt-to-equity ratio?
Tyra Biosciences, Inc. (TYRA) had a debt-to-equity ratio of 0.06 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Tyra Biosciences, Inc.'s return on assets (ROA)?
Tyra Biosciences, Inc. (TYRA) had a return on assets of -23.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Tyra Biosciences, Inc.'s cash runway?
Based on fiscal year 2024 data, Tyra Biosciences, Inc. (TYRA) had $92.0M in cash against an annual operating cash burn of $69.8M. This gives an estimated cash runway of approximately 16 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Tyra Biosciences, Inc.'s Piotroski F-Score?
Tyra Biosciences, Inc. (TYRA) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Tyra Biosciences, Inc.'s earnings high quality?
Tyra Biosciences, Inc. (TYRA) has an earnings quality ratio of 0.81x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.